Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170763 | 0.96 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL20877646 | 0.94 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL19817529 | 0.94 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL20877621 | 0.94 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL25060963 | 0.94 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24803728 | 0.88 | ADRA2A (0.31) | ADRA2AADRA2BADRA2C | |
| SCHEMBL25644900 | 0.86 | GRM1 (0.35) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL31003113 | 0.85 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24997680 | 0.82 | GRM1 (0.38) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL4203445 | 0.79 | HTR2C (0.43) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125918-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230054854-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | RETROVIROX, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110129444-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110129444-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | CD74, HLA-DRB1, MICA | ADRA2A 634/4885ADRA2B 1241/4885ADRA2C 579/4885 |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRA2A 4400/4885ADRA2B 4470/4885ADRA2C 3995/4885 |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | ADRA2A 3042/4885ADRA2B 2696/4885ADRA2C 3499/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | ADRA2A 3925/4885ADRA2B 2927/4885ADRA2C 2888/4885 |
| US-20110059047-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRA2A 4400/4885ADRA2B 4470/4885ADRA2C 3995/4885 |
| US-20230054854-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | ADRA2A 4304/4885ADRA2B 4399/4885ADRA2C 4418/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | ADRA2A 2890/4885ADRA2B 2345/4885ADRA2C 1173/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | ADRA2A 560/4885ADRA2B 628/4885ADRA2C 598/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | ADRA2A 4299/4885ADRA2B 4556/4885ADRA2C 4011/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | ADRA2A 2557/4885ADRA2B 2445/4885ADRA2C 1643/4885 |
| US-20110129444-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ADRA2A 4478/4885ADRA2B 4524/4885ADRA2C 4066/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | ADRA2A 2847/4885ADRA2B 2555/4885ADRA2C 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.